The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Open accessAbstract
Background Patients with systemic lupus erythematosus have T-cell dysfunction that has been attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been developed as a medication under the generic designation of sirolimus. We assessed safety, tolerance, and efficacy of sirolimus in a prospective, biomarker-driven, open-label clinical trial.Methods We did a single-arm, open-label, phase 1/2 trial of sirolimus in patients with active systemic lupus erythematosus disease unresponsive to, or intolerant of, conventional medications at the State University of New York Upstate Medical University (Syracuse, NY, USA). Eligible participants (aged ≥18 years) had active systemic lupus erythematosus fulfilling four or more of 11 diagnostic criteria defined by the American College of Rheumatology. We excluded patients with allergy or intolerance to sirolimus, patients with life-threatening manifestations of systemic lupus erythematosus, proteinuria, a urine protein to creatinine ratio higher than 0·5, anaemia, leucopenia, or thrombocytopenia. Patients received oral sirolimus at a starting dose of 2 mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL. Patients were treated with sirolimus for 12 months. Safety outcomes included tolerance as assessed by the occurrence of common side-effects. The primary efficacy endpoint was decrease in disease activity, assessed using the British Isles Lupus Assessment Group (BILAG) index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Blood samples of 56 matched healthy individuals were obtained as controls for immunobiological outcomes monitored at each visit. The primary efficacy endpoint was assessed in all patients who completed 12 months of treatment, and all patients who received at least one dose of treatment were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT00779194.Findings Between March 9, 2009, and Dec 8, 2014, 43 patients were enrolled, three of whom did not meet eligibility criteria. 11 of the 40 eligible patients discontinued study treatment because of intolerance (n=2) or non-compliance (n=9). SLEDAI and BILAG disease activity scores were reduced during 12 months of treatment in 16 (55%) of 29 patients who completed treatment. Mean SLEDAI score decreased from 10·2 (SD 5·6) at enrolment to 4·8 (4·5) after 12 months of treatment (p<0·001) and the mean total BILAG index score decreased from 28·4 (12·4) at enrolment to 17·4 (10·7) after 12 months of treatment (p<0·001). The mean daily dose of prednisone required to control disease activity decreased from 23·7 mg (SD 9·6) to 7·2 mg (2·3; p<0·001) after 12 months of treatment. Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months. CD8+ memory T cells were selectively expanded in SRI-responders. Patient liver function and lymphocyte counts were unchanged. Although HDL-cholesterol (Z=-2·50, p=0·012), neutrophil counts (Z=-1·92, p=0·054), and haemoglobin (Z=-2·83, p=0·005) were moderately reduced during treatment, all changes occurred within a range that was considered safe. Platelet counts were slightly elevated during treatment (Z=2·06, p=0·0400).Interpretation These data show that a progressive improvement in disease activity is associated with correction of pro-inflammatory T-cell lineage specification in patients with active systemic lupus erythematosus during 12 months of sirolimus treatment. Follow-up placebo-controlled clinical trials in diverse patient populations are warranted to further define the role of mTOR blockade in treatment of systemic lupus erythematosus.Funding Pfizer, the National Institutes of Health, and the Central New York Community Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, mTOR blockade in patients with SLE treated with N-acetylcysteine or rapamycin reduces both pro-inflammatory T cells and disease activity85,260, suggesting that dietary supplementation or drugs that regulate mitochondrial dynamics might constitute novel therapeutic avenues for mitigating autoantibody production in SLE.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [260]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
Tsokos, G. C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,814
Navarra, S., Guzmán, R., Gallacher, A., Hall, S., Levy, R. A., Jimenez, R., Li, E. K., Thomas, M., Kim, H., Leon, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,078
Vézina, C., KUDELSKI, A., & Sehgal, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,691
Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis
Xia, J., & Wishart, D. S. (2016) · Current Protocols in Bioinformatics · doi:10.1002/cpbi.11 · Cited by 1,560
Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P., & Snyder, S. H. (1994) · Cell · doi:10.1016/0092-8674(94)90570-3 · Cited by 1,509
Cited by
Sorted by citations
Items 101–200 of 411
What's New in the Treatment of Systemic Lupus Erythematosus
Liossis, S. C., & Staveri, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.655100 · Cited by 47
T Cells in Systemic Lupus Erythematosus
Paredes, J. L., Fernandez‐Ruiz, R., & Niewold, T. B. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.005 · Cited by 46
mTOR-Related Cell-Clearing Systems in Epileptic Seizures, an Update
Limanaqi, F., Biagioni, F., Busceti, C. L., Fabrizi, C., Frati, A., & Fornai, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051642 · Cited by 48
Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity
Liebmann, M., Korn, L., Janoschka, C., Albrecht, S., Lauks, S., Herrmann, A. M., Schulte‐Mecklenbeck, A., Schwab, N., Schneider‐Hohendorf, T., Eveslage, M., et al. (2021) · Brain · doi:10.1093/brain/awab307 · Cited by 44
Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders
Mitra, S., Banik, A., Saurabh, S., Maulik, M., & Khatri, S. (2022) · Journal of Neuroscience · doi:10.1523/jneurosci.0998-21.2022 · Cited by 45
B cell activation via immunometabolism in systemic lupus erythematosus
Iwata, S., Hajime, M., & Tanaka, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1155421 · Cited by 44
Winans, T., Oaks, Z., Choudhary, G., Patel, A., Huang, N., Faludi, T., Krakkó, D., Nolan, J. P., Lewis, J., Blair, S., et al. (2023) · Journal of Autoimmunity · doi:10.1016/j.jaut.2023.103112 · Cited by 44
Self-citationFeng, Y., Xiao, Y., Yan, H., Wang, P., Zhu, W., Cassady, K. M., Zou, Z., Wang, K., Chen, T., Yao, Q., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00110 · Cited by 44
Peng, L., Wu, C., Hong, R., Sun, Y., Qian, J., Zhao, J., Wang, Q., Tian, X., Wang, Y., Li, M., et al. (2020) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x20953336 · Cited by 44
Klapan, K., Simon, D., Karaulov, A. V., Gomzikova, M. O., Rizvanov, A. A., Yousefi, S., & Simon, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.844756 · Cited by 44
Cytotoxic CD161−CD8+ TEMRA cells contribute to the pathogenesis of systemic lupus erythematosus
Xiong, H., Cui, M., Kong, N., Jing, J., Xu, Y., Liu, X., Yang, F., Xu, Z., Yan, Y., Zhao, D., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104507 · Cited by 43
Nouwen, L. V., & Everts, B. (2020) · Cells · doi:10.3390/cells9010161 · Cited by 43
Yang, S., Zhang, H., Shi, S., Zhu, Y.-Q., Song, N., Dai, Q., Zhang, W., Gui, M., & Zhang, H. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867326666181126165139 · Cited by 41
The pathological role of B cells in systemic lupus erythematosus: From basic research to clinical
Feng, Y., Yang, M., Wu, H., & Lu, Q. (2019) · Autoimmunity · doi:10.1080/08916934.2019.1700232 · Cited by 41
Yang, W., Yu, T., & Cong, Y. (2022) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbac018 · Cited by 42
Inhibitory targeting cGAS-STING-TBK1 axis: Emerging strategies for autoimmune diseases therapy
Zhang, M., Zou, Y., Zhou, X., & Zhou, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954129 · Cited by 43
Immunometabolic shifts in autoimmune disease: Mechanisms and pathophysiological implications
Chen, Y., Lin, Q., Cheng, H., Xiang, Q., Zhou, W., Wu, J., & Wang, X. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103738 · Cited by 41
The Immunomodulatory Effect of Alpha-Lipoic Acid in Autoimmune Diseases
Liu, W., Shi, L., & Li, S. (2019) · BioMed Research International · doi:10.1155/2019/8086257 · Cited by 40
Miller, S. D., Tsou, P., Coit, P., Gensterblum‐Miller, E., Renauer, P. A., Rohraff, D. M., Kilian, N. C., Schonfeld, M., & Sawalha, A. H. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214323 · Cited by 40
Katsuyama, T., Juárez, I., Krishfield, S., Kyttaris, V. C., & Moulton, V. R. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa094 · Cited by 40
Metabolite Transporters as Regulators of Immunity
Weiss, H. J., & Angiari, S. (2020) · Metabolites · doi:10.3390/metabo10100418 · Cited by 41
Caza, T. N., Wijewardena, C., Al-Rabadi, L. F., & Perl, A. (2022) · Translational research · doi:10.1016/j.trsl.2022.03.004 · Cited by 40
Self-citationAutophagy in lupus nephritis: A delicate balance between regulation and disease
Podestà, M. A., Faravelli, I., & Ponticelli, C. E. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103132 · Cited by 39
TCR-α/β CD4− CD8− double negative T cells arise from CD8+ T cells
Rodríguez‐Rodríguez, N., Flores-Mendoza, G., Apostolidis, S. A., Rosetti, F., Tsokos, G. C., & Crispín, J. C. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ab0120-548r · Cited by 39
Systemic lupus erythematosus (SLE): emerging therapeutic targets
Mathias, L. M., & Stohl, W. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1832464 · Cited by 39
Geier, C., & Perl, A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102984 · Cited by 40
Self-citationImmunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention
O’Shea, A. E., Valdera, F. A., Ensley, D. C., Smolinsky, T. R., Cindass, J. L., Bohan, P. M. K., Hickerson, A. T., Carpenter, E. L., McCarthy, P. M., Adams, A. M., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109095 · Cited by 40
mTORC1 links pathology in experimental models of Still’s disease and macrophage activation syndrome
Huang, Z., You, X., Chen, L., Du, Y., Brodeur, K. E., Jee, H., Wang, Q., Linder, G., Darbousset, R., Cunin, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34480-6 · Cited by 39
Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases
Lu, Y., Wang, Y., Ruan, T., Wang, Y., Ju, L., Zhou, M., Liu, L., Dengfu, Y., & Yao, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1536020 · Cited by 39
Metabolic regulation of pathogenic autoimmunity: therapeutic targeting
Teng, X., Cornaby, C., Li, W., & Morel, L. M. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.07.001 · Cited by 38
mTOR pathway activation in large vessel vasculitis
Maciejewski‐Duval, A., Comarmond, C., Leroyer, A. S., Zaidan, M., Joncour, A. L., Desbois, A. C., Fouret, J.-P., Koskas, F., Cluzel, P., Garrido, M., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.07.013 · Cited by 40
Low Production of Reactive Oxygen Species Drives Systemic Lupus Erythematosus
Urbonaviciute, V., Luo, H., Sjöwall, C., Bengtsson, A. A., & Holmdahl, R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.001 · Cited by 37
Metabolic Fitness of T Cells in Autoimmune Disease
Wu, B., Goronzy, J. J., & Weyand, C. M. (2020) · Immunometabolism · doi:10.20900/immunometab20200017 · Cited by 37
Metabolic rewiring: a new master of Th17 cell plasticity and heterogeneity
Papadopoulou, G., & Xanthou, G. (2021) · FEBS Journal · doi:10.1111/febs.15853 · Cited by 39
Modulation of the immunity and inflammation by autophagy
Gan, T., Qu, S., Zhang, H., & Zhou, S. (2023) · MedComm · doi:10.1002/mco2.311 · Cited by 39
B cell metabolism in autoimmune diseases: signaling pathways and interventions
Li, J., Zhao, M., Luo, W., Huang, J., Zhao, B., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1232820 · Cited by 36
Mitochondrial Dysfunction in Systemic Lupus Erythematosus with a Focus on Lupus Nephritis
Halfon, M., Tankeu, A. T., & Ribi, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116162 · Cited by 36
Zhao, L., Zhou, X., Zhou, X., Wang, H., Gu, L., Ke, Y., Zhang, M., Ji, X., & Yang, X. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155119 · Cited by 36
Reactive oxygen species: The Yin and Yang in (auto-)immunity
Scherlinger, M., & Tsokos, G. C. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102869 · Cited by 38
Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases
Wyman, B., & Perl, A. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000687 · Cited by 35
Self-citationWen, H., Wang, J., Zhang, S., Luo, J., Zhao, X., Zhang, C., Wang, C., Hu, F.-Y., Zheng, X.-J., Cheng, T., et al. (2019) · Journal of Immunology Research · doi:10.1155/2019/7684352 · Cited by 34
Amino Acid Metabolism in Lupus
Kono, M., Yoshida, N., & Tsokos, G. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623844 · Cited by 36
MTOR Signaling and Metabolism in Early T Cell Development
Werlen, G., Jain, R., & Jacinto, E. (2021) · Genes · doi:10.3390/genes12050728 · Cited by 35
Piranavan, P., & Perl, A. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108781 · Cited by 34
Self-citationJi, J., Fu, T., Dong, C., Zhu, W., Yang, J., Kong, X., Zhang, Z., Bao, Y., Zhao, R. Z., Ge, X., et al. (2019) · Aging · doi:10.18632/aging.102052 · Cited by 34
Zhang, J., Zhao, L., Wang, J., Cheng, Z., Sun, M., Zhao, J., Liu, B., Liu, X., Wen, Z., & Li, Z. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41084 · Cited by 33
Recent Advances in Lupus B Cell Biology: PI3K, IFNγ, and Chromatin
Bacalao, M. A., & Satterthwaite, A. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.615673 · Cited by 33
Lupus susceptibility gene Esrrg modulates regulatory T cells through mitochondrial metabolism
Li, W., Gong, M., Park, Y. P., Elshikha, A. S., Choi, S., Brown, J., Kanda, N., Yeh, W.-I., Peters, L. D., Titov, A. A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.143540 · Cited by 33
New developments in systemic lupus erythematosus
Tsang-A-Sjoe, M. W. P., & Bultink, I. E. M. (2021) · Rheumatology · doi:10.1093/rheumatology/keab498 · Cited by 33
Jeong, J., Choi, Y. J., & Lee, H. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.860146 · Cited by 33
Mohammadnezhad, L., Azgomi, M. S., Manna, M. P. L., Sireci, G., Rizzo, C., Badami, G. D., Tamburini, B., Dieli, F., Guggino, G., & Caccamo, N. (2022) · Cells · doi:10.3390/cells11101663 · Cited by 33
Yung, S., Yap, D. Y. H., & Chan, T. M. (2020) · F1000Research · doi:10.12688/f1000research.22438.1 · Cited by 32
Tatar, G., Ozyurt, E., & Turhan, K. (2020) · Biotechnology Progress · doi:10.1002/btpr.3110 · Cited by 32
New insights into the metabolism of Th17 cells
Kono, M. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2140503 · Cited by 33
Immune cell metabolism in autoimmunity
Teng, X., Li, W., Cornaby, C., & Morel, L. M. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13277 · Cited by 33
Efferocytosis: Unveiling its potential in autoimmune disease and treatment strategies
Xing, J., Wang, K., Xu, Y.-C., Pei, Z.-J., Yu, Q., Liu, X., Dong, Y.-L., Li, S., Chen, Y., Zhao, Y., et al. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103578 · Cited by 31
Mitochondria as a key player in systemic lupus erythematosus
Quintero-González, D. C., Muñoz-Urbano, M., & Vásquez, G. M. (2022) · Autoimmunity · doi:10.1080/08916934.2022.2112181 · Cited by 31
The epigenetic face of lupus: Focus on antigen-presenting cells
Wardowska, A. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106262 · Cited by 34
PD-1 immunobiology in glomerulonephritis and renal cell carcinoma
Curran, C. S., & Kopp, J. B. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02257-6 · Cited by 30
mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus
Zhao, X., Wang, S., Wang, S., Xie, J., & Cui, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109153 · Cited by 36
Metabolism of T Lymphocytes in Health and Disease
Gaber, T., Chen, Y., Krauß, P.-L., & Buttgereit, F. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.002 · Cited by 32
Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis
Gao, H., Liu, S., Mai, Y., Wang, Y., Zhang, X., Zheng, S., Luo, C., & Pan, C. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223736 · Cited by 29
Systematic review of sirolimus in dermatological conditions
Swarbrick, A. W., Frederiks, A. J., & Foster, R. S. (2021) · Australasian Journal of Dermatology · doi:10.1111/ajd.13671 · Cited by 29
A cellular overview of immunometabolism in systemic lupus erythematosus
Psarras, A., & Clarke, A. J. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqad005 · Cited by 29
Double-Negative T (DNT) Cells in Patients with Systemic Lupus Erythematosus
Poddighe, D., Dossybayeva, K., Kozhakhmetov, S., Розенсон, Р., & Assylbekova, M. (2024) · Biomedicines · doi:10.3390/biomedicines12010166 · Cited by 28
Immmunometabolism of systemic lupus erythematosus
Furment, M. M., & Perl, A. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.109939 · Cited by 28
Self-citationRedox Pathogenesis in Rheumatic Diseases
Laniak, O. T., Winans, T., Patel, A., Park, J. S., & Perl, A. (2024) · ACR Open Rheumatology · doi:10.1002/acr2.11668 · Cited by 28
Self-citationDistinct Tissue-Specific Roles for the Disease-Associated Autophagy Genes ATG16L2 and ATG16L1
Khor, B., Conway, K. L., Omar, A. S., Biton, M., Haber, A. L., Rogel, N., Baxt, L. A., Begun, J., Kuballa, P., Gagnon, J. D., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800419 · Cited by 28
Chu, Y., Zhao, C., Zhang, B., Wang, X., Wang, Y., An, J., & Chen, J. (2019) · Lupus · doi:10.1177/0961203319877239 · Cited by 28
The ‘Treg paradox’ in inflammatory arthritis
Schnell, J. T., Briviesca, R. L., Kim, T., Charbonnier, L., Henderson, L. A., van Wijk, F., & Nigrovic, P. A. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01190-w · Cited by 27
Bánki, K., & Perl, A. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103781 · Cited by 27
Self-citationInteractions of Autophagy and the Immune System in Health and Diseases
Pant, A., Yao, X., Lavedrine, A., Viret, C., Dockterman, J., Chauhan, S. C., Shi, C.-S., Manjithaya, R. R., Cadwell, K., Kufer, T. A., et al. (2022) · Autophagy Reports · doi:10.1080/27694127.2022.2119743 · Cited by 28
Zheng, X., Tsou, P., & Sawalha, A. H. (2020) · Immunometabolism · doi:10.20900/immunometab20200013 · Cited by 27
Nguyen, T., Duong, V., Vo, D.-K., Jo, J., & Maeng, H. (2021) · Molecules · doi:10.3390/molecules26020425 · Cited by 27
Remodeling of T-cell mitochondrial metabolism to treat autoimmune diseases
Lin, L., Ren, R., Xiong, Q., Zheng, C., Yang, B., & Wang, H. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103583 · Cited by 28
Lupus Nephritis: Current Perspectives and Moving Forward
Lichtnekert, J., Anders, H., & Lech, M. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s363722 · Cited by 26
Wu, C., Wang, Q., Xu, D., Li, M., & Zeng, X. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa645 · Cited by 27
Immunosenescence in autoimmune diseases
Hu, H., Zhang, G., Chen, T., Liu, Y., Meng, L., Holmdahl, R., Dai, L., & Zhao, Y. C. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103805 · Cited by 30
Hu, Y., Zhao, Q., Dai, H., Wu, Y., Tang, X., Zhang, N., Jiang, H., Rui, H., & Liu, B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1687755 · Cited by 26
Godavarthy, A., Kelly, R., Jimah, J. R., Beckford, M., Caza, T. N., Fernández, D., Huang, N., Duarte, M., Lewis, J., Fadel, H. J., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.134010 · Cited by 25
Self-citationManagement of cardiovascular disease in patients with systemic lupus erythematosus
Piranavan, P., & Perl, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1770227 · Cited by 26
Self-citationSong, X., Gao, J., Liu, H., Liu, X.-H., & Tang, K. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111289 · Cited by 25
Wu, J., Pang, T., Lin, Z., Zhao, M., & Jin, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965941 · Cited by 25
STING guides the STX17-SNAP29-VAMP8 complex assembly to control autophagy
Song, X., Xi, Y., Dai, M., Li, T., Du, S., Zhu, Y., Li, M., Li, Y., Liu, S., Ding, X., et al. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100147 · Cited by 25
Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus
Prete, M., Leone, P., Frassanito, M. A., Desantis, V., Marasco, C., Cicco, S., Dammacco, F., Vacca, A., & Racanelli, V. (2018) · Lupus · doi:10.1177/0961203318797425 · Cited by 27
Wei, S., Xie, S., Yang, Z., Peng, X., Gong, L., Zhao, K., Zeng, K., & Lai, K. (2018) · Lupus · doi:10.1177/0961203318819131 · Cited by 25
The role of mTOR signaling pathway in systemic lupus erythematosus and systemic vasculitis
Michailidou, D., Gartshteyn, Y., Askanase, A., & Perl, A. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103910 · Cited by 26
Self-citationJiang, N., Li, M., Zhang, H., Duan, X., Li, X., Fang, Y., Li, H., Yang, P., Luo, H., Wang, Y., et al. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000617 · Cited by 25
Autophagy in Rheumatic Diseases: Role in the Pathogenesis and Therapeutic Approaches
Celia, A. I., Colafrancesco, S., Barbati, C., Alessandri, C., & Conti, F. (2022) · Cells · doi:10.3390/cells11081359 · Cited by 24
Regulation of immune cell metabolism in health and disease: Special focus on T and B cell subsets
Chakraborty, S., Khamaru, P., & Bhattacharyya, A. (2022) · Cell Biology International · doi:10.1002/cbin.11867 · Cited by 24
The Influence of Diet and Obesity on Gene Expression in SLE
Cava, A. L. (2019) · Genes · doi:10.3390/genes10050405 · Cited by 27
Up-and-Coming Drugs for the Treatment of Vitiligo
Seong, S. H., & Oh, S. H. (2024) · Annals of Dermatology · doi:10.5021/ad.24.038 · Cited by 23
Metabolic control of T cells in autoimmunity
Kono, M., Yoshida, N., & Tsokos, G. C. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000685 · Cited by 23
Tzeng, H., & Chyuan, I. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.03.019 · Cited by 23
Terrell, M., & Morel, L. M. (2022) · Endocrinology · doi:10.1210/endocr/bqac067 · Cited by 23
Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus
Ohmes, J., Comdühr, S., Akbarzadeh, R., Riemekasten, G., & Humrich, J. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007078 · Cited by 23
Emerging biologic therapies for systemic lupus erythematosus
Kato, H., & Kahlenberg, J. M. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001003 · Cited by 23
Downregulation of miR-633 activated AKT/mTOR pathway by targeting AKT1 in lupus CD4 + T cells
Chen, S., Wang, Y., Qin, H., Lin, J., Xie, L., Chen, S., Liang, J. F., & Xu, J. (2019) · Lupus · doi:10.1177/0961203319829853 · Cited by 23
Chimeric antigen receptor T-cell therapy in autoimmune diseases
Liu, J., Yan, Z., & Hai, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1492552 · Cited by 23
mTOR Signaling Network in Cell Biology and Human Disease
Yu, J. J., & Goncharova, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416142 · Cited by 22
Self-citation
Metadata
- Authors
- Lai, Z.-W., Kelly, R., Winans, T., Marchena, I., Shadakshari, A., Yu, J., Dawood, M., Garcia, R., Tily, H., Francis, L., Faraone, S. V., Phillips, P. E., & Perl, A.
- Affiliations
- SUNY Upstate Medical University (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 391
- Issue
- 10126
- Pages
- 1186-1196
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC5891154
- OpenAlex
- W2791734424
- Cited by
- 412
- References
- 43
- Citations by year
- 2026: 35 · 2025: 43 · 2024: 51 · 2023: 35 · 2022: 67 · 2021: 44 · 2020: 56 · 2019: 49 · 2018: 31
- FWCI
- 38.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Pfizer
- Syracuse University
- National Institute of Allergy and Infectious Diseases (R01AI048079, R01AI122176, R56AI048079, R01AI072648, R34AI141304)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- rapamycin, systemic lupus erythematosus, mTOR inhibition, T cell dysfunction, refractory lupus, disease activity, BILAG index, SLEDAI, drug safety and tolerability, biomarker-driven treatment, mTOR inhibitors, immunosuppressive therapy, dose adjustment, adverse events, lupus nephritis, proteinuria, thrombocytopenia
- MeSH terms
- Adolescent, Adult, Aged, Drug Tolerance, Female, Humans, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Male, Middle Aged, Prospective Studies, Treatment Outcome, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
